S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)
To compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR)-positive, and human epidermal growth factor receptor (HER)2-negative breast cancer.
This research study is led by Dr. Grace Makari-Judson.
Contact Name: Ruth Barham, 413-794-3186
August 28, 2012
Cancer - Breast,
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Invasive non-metastatic breast cancer; ER/PR positive; HER2 negative
Interventional (Clinical Trial), Randomized